Agarwal SK, Mateo CM & Marx SJ 2009 Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. Journal of Clinical Endocrinology and Metabolism 94 1826-1834. (doi:10.1210/jc.2008-2083)
CBTRUS (2011). CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL.Website:www.cbtrus.org.
Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, Walsh PC, Meyers DA, Isaacs WB & Xu J 2004 A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Research 64 1997-1999. (doi:10.1158/0008-5472.CAN-03-2340)
Costa-Guda J, Marinoni I, Molatore S, Pellegata NS &Arnold A 2011 Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. Journal of Clinical Endocrinology and Metabolism 96 E701-E706. (doi:10. 1210/jc.2010-1338)
Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T et al. 2006a Clinical characterization of familial isolated pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 91 3316-3323. (doi:10.1210/jc.2005-2671)
Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A 2006b High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 91 4769-4775. (doi:10.1210/jc.2006-1668)
Daly AF, Vanbellinghen JF, Khoo SK, Jaffrain-Rea ML, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez- Roqueplo AP, Tamburrano G et al. 2007 Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. Journal of Clinical Endocrinology and Metabolism 92 1891-1896. (doi:10.1210/jc.2006-2513)
Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, Naves LA, Ebeling T, Karhu A, Raappana A et al. 2010 Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an International collaborative study. Journal of Clinical Endocrinology and Metabolism 95 E373-E383. (doi:10.1210/jc.2009- 2556)
Dennis JW, Granovsky M & Warren CE 1999 Glycoprotein glycosylation and cancer progression. Biochimica et Biophysica Acta 1473 21-34. (doi:10.1016/S0304-4165(99)00167-1)
Fernandez A, Karavitaki N & Wass JA 2010 Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology 72 377-382. (doi:10.1111/j.1365-2265.2009.03667.x)
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM et al. 1996 A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27- deficient mice. Cell 85 733-744. (doi:10.1016/S0092- 8674(00)81239-8)
Fero ML, Randel E, Gurley KE, Roberts JM & Kemp CJ 1998 The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396 177-180. (doi:10.1038/24179)
Fritz A, Walch A, Piotrowska K, Rosemann M, Schäffer E, Weber K, Timper A, Wildner G, Graw J, Höfler H et al. 2002 Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Research 62 3048-3051. (Pubitemid 34602393)
Georgitsi M, Raitila A, Karhu A, van der Luijt RB, Aalfs CM, Sane T, Vierimaa O, Mäkinen MJ, Tuppurainen K, Paschke R et al. 2007a Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. Journal of Clinical Endocrinology and Metabolism 92 3321-3325. (doi:10.1210/jc.2006-2843)
Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Mäkinen MJ, Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T et al. 2007b Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. PNAS 104 4101-4105. (doi:10.1073/pnas.0700004104)
Igreja S, Chahal HS, Akker SA, Gueorguiev M, Popovic V, Damjanovic S, Burman P, Wass JA, Quinton R, Grossman AB et al. 2009 Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and aryl hydrocarbon receptor-interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations. Clinical Endocrinology 70 259-264. (doi:10.1111/j.1365-2265.2008.03379.x)
Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, Chapple JP, Trivellin G, Gueorguiev M, Guegan K et al. 2010 Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Human Mutation 31 950-960. (doi:10.1002/humu.21292)
Ikeda H, Yoshimoto T & Shida N 1997 Molecular analysis of p21 and p27 genes in human pituitary adenomas. British Journal of Cancer 76 1119-1123. (doi:10.1038/ bjc.1997.521)
Jaffrain-Rea ML, Daly AF, Angelini M, Petrossians P, Bours V & Beckers A 2011 Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications. Expert Review of Endocrinology &Metabolism 6 195-214 (doi:10.1586/eem.10.87). (doi:10.1586/eem.10.87)
Jin L, Qian X, Kulig E, Sanno N, Scheithauer BW, Kovacs K, Young WF Jr & Lloyd RV 1997 Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. American Journal of Pathology 151 509-519. (Pubitemid 27330070)
Kawamata N, Morosetti R, Miller CW, Park D, Spirin KS, Nakamaki T, Takeuchi S, Hatta Y, Simpson J, Wilcyznski S et al. 1995 Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Research 55 2266-2269.
Kiyokawa H, Kineman RM, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA & Koff A 1996 Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85 721-732. (doi:10.1016/S0092- 8674(00)81238-6)
Marinoni I & Pellegata NS 2011 p27kip1: a new multiple endocrine neoplasia gene? Neuroendocrinology 93 19-28. (doi:10.1159/000320366)
McAllister SS, Becker-Hapak M, Pintucci G, Pagano M &Dowdy SF 2003 Novel p27kip1 C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Molecular and Cellular Biology 23 216-228. (doi:10.1128/MCB.23.1.216-228.2003)
Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, degli Uberti EC, Zatelli MC & Pellegata NS 2010 A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Human Mutation 31 E1825-E1835. (doi:10.1002/humu. 21354)
Morosétti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M & Koeffler HP 1995 Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 86 1924-1930.
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY & Nakayama K 1996 Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 707-720. (doi:10.1016/S0092-8674(00)81237-4)
Ojeda D, Lakhal B, Fonseca DJ, Braham R, Landolsi H, Mateus HE, Restrepo CM, Elghezal H, Saâd A & Laissue P 2011 Sequence analysis of the CDKN1B gene in patients with premature ovarian failure reveals a novel mutation potentially related to the phenotype. Fertility and Sterility 95 2658-2660. (doi:10.1016/j.fertnstert. 2011.04.045)
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF & Rolfe M 1995 Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269 682-685. (doi:10.1126/science.7624798)
Pappa V, Papageorgiou S, Papageorgiou E, Panani A, Boutou E, Tsirigotis P, Dervenoulas J, Economopoulos T & Raptis S 2005 A novel p27 gene mutation in a case of unclassified myeloproliferative disorder. Leukemia Research 29 229-231. (doi:10.1016/j.leukres.2004.06.007)
Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Höfler H, Fend F, Graw J & Atkinson MJ 2006 Germ-line mutations in p27 Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. PNAS 103 15558-15563. (doi:10.1073/pnas.0603877103)
Takeuchi S, Koeffler HP, Hinton DR, Miyoshi I, Melmed S &Shimon I 1998 Mutation and expression analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in pituitary tumors. Journal of Endocrinology 157 337-341. (doi:10.1677/joe.0.1570337)
Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi CL, Yaneva M, Urban JD, Petrossians P, Elenkova AP, Tabarin A et al. 2011 High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. European Journal of Endocrinology 165 509-515 (DOI: 10.1530/EJE-11-0304). (doi:10.1530/EJE-11-0304)
Vervoorts J & Lüscher B 2008 Post-translational regulation of the tumor suppressor p27(KIP1). Cellular and Molecular Life Sciences 65 3255-3264. (doi:10.1007/ s00018-008-8296-7)
Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R et al. 2006 Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312 1228-1230. (doi:10.1126/science.1126100)
